Ocular Therapeutix (NASDAQ:OCUL) prices its initial public offering of 5M shares of common stock at $13.00 per share. Underwriters over-allotment is 750K shares. Trading in the NASDAQ Global Market-listed issue starts today.
The company uses its proprietary hydrogel technology to develop ophthalmic drug delivery systems and medical devices. It launched its ReSure Sealant for corneal incisions in February 2014.